MPD: Project measures / variables set: Wiltshire4 monocytes_Dox

Project measures / variables set: Wiltshire4 monocytes_Dox

ID, description, units	MPD:52433 monocytes_Dox monocytes, percent viability [%] doxorubicin study
Measures	• dose [µM]: • control • 0.046 • 0.137 • 1.235 • 11.1 • 100
Data set, strains	Wiltshire4 inbred w/CC7 35 strains sex: m age: 10wks
Procedure	immune cell quantification
Comparison	control group vs. multiple treatment / dosage groups
Ontology mappings	VT:0000223 monocyte quantity VT:0010487 response to xenobiotic stimulus trait MA:0000141 spleen MP:0008872 abnormal physiological response to xenobiotic MP:0012441 abnormal monocyte cell number

SIDE-BY-SIDE STRAIN CURVES

ANOVA, Q-Q NORMALITY ASSESSMENT

ANOVA Summary

Factor	DF	Sum of squares	Mean sum of squares	F value	p-value (Pr>F)
dose	5	629363.3171	125872.6634	1030.6103	< 0.0001
strain	33	49265.3346	1492.8889	12.2234	< 0.0001
dose:strain	165	97877.3723	593.1962	4.8569	< 0.0001
Residuals	593	72425.5223	122.1341

Q-Q normality assessment based on residuals

INDIVIDUAL MEASURES

	Project	ID		Treatment	Measure / Variable Description	Panel	Strains tested	Sex	Age
	Wiltshire4	52433	immune cell quantification	doxorubicin	monocytes, percent viability [%] control monocytes_Dox_ctrl	inbred w/CC7	35	m	10wks
	Wiltshire4	52434	immune cell quantification	doxorubicin	monocytes, percent viability [%] dose: 0.046 µM monocytes_Dox_A	inbred w/CC7	35	m	10wks
	Wiltshire4	52435	immune cell quantification	doxorubicin	monocytes, percent viability [%] dose: 0.137 µM monocytes_Dox_B	inbred w/CC7	35	m	10wks
	Wiltshire4	52436	immune cell quantification	doxorubicin	monocytes, percent viability [%] dose: 1.235 µM monocytes_Dox_C	inbred w/CC7	35	m	10wks
	Wiltshire4	52437	immune cell quantification	doxorubicin	monocytes, percent viability [%] dose: 11.1 µM monocytes_Dox_D	inbred w/CC7	35	m	10wks
	Wiltshire4	52438	immune cell quantification	doxorubicin	monocytes, percent viability [%] dose: 100 µM monocytes_Dox_E	inbred w/CC7	35	m	10wks